NCT05853965

Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory T(11;14) Multiple Myeloma

Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory T(11;14) Multiple Myeloma (Phase I/IIa) the BELI(E)VE-Trial

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 45 (estimated)
• Sponsor: Universitätsklinikum Hamburg-Eppendorf · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to learn about the safety and efficacy of the drug combination belantamab mafodotin and venetoclax, with or without the addition of dexamethasone, in patients with relapsed/refractory multiple myeloma bearing the translocation t(11;14)

Conditions

• Multiple Myeloma
• Multiple Myeloma in Relapse

Interventions

Type	Name	Description
DRUG	Belantamab mafodotin, Venetoclax	Belantamab mafodotin (IV) Venetoclax (PO)

Timeline

• Start date: 2023-06-28
• Primary completion: 2026-11-01
• Completion: 2026-12-01
• First posted: 2023-05-11
• Last updated: 2025-03-30

Locations

5 sites across 1 country: Germany